Differences in the Length of Gag Proteins among Different HIV Type 1 Subtypes
- 1 October 2005
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 21 (10) , 886-893
- https://doi.org/10.1089/aid.2005.21.886
Abstract
The effect of HIV-1 subtype on Gag protein length was examined in 122 individuals infected with different HIV-1 clades. Except for the P1 protein, a wide variation in the Gag proteins length was noticed. P2 was significantly shorter in 68 non-B with respect to 54 subtype B viruses. Nearly 85% of subtype B gag sequences harbored P2 with 14 or more amino acid (aa) residues, while 75% of non-B subtypes had P2 with 13 or less aa (p < 0.0001). The P7 protein was one residue shorter in 64.2% of non-B specimens but only in 9.3% of subtype B isolates (p = 0.0001). Overall, the P6gag protein length was modified by the presence of insertions, deletions, and stop codons in 89 (73%) of the tested population, but was mainly dependent of changes in non- B compared to B viruses (97% vs. 42.6%, p < 0.0001). However, insertions at P6gag (from 1 to 9 aa) were significantly more frequent in B than in non-B viruses (33.3% vs. 4.4%; p = 0.00002). Overall, conserved Gag residues and aa motifs, regardless of the genetic subtype, were 68.7% in P1, 54% in P7, 33.3% in P2, and 25% in P6gag proteins. In summary, length variation in Gag proteins is extensive across different HIV-1 subtypes, and could influence protein structure and function. The effect of Gag variation on the viral cycle among different HIV-1 clades needs to be further investigated.Keywords
This publication has 39 references indexed in Scilit:
- Effects of mutations in an HIV‐1 gag gene containing a 107‐codon tandem repeat in the matrix region on assembly and processing of the protein productJournal of Medical Virology, 2004
- Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral TherapyAIDS Research and Human Retroviruses, 2004
- Effects of a Single Amino Acid Substitution within thep2 Region of Human Immunodeficiency Virus Type 1 on Packagingof Spliced ViralRNAJournal of Virology, 2003
- Genetic diversity of HIV in AfricaAIDS, 2003
- Variability at Human Immunodeficiency Virus Type 1 Subtype C Protease Cleavage Sites: an Indication of Viral Fitness?Journal of Virology, 2003
- Resistance to Antiretroviral Agents in Individuals with HIV-1 Non-B SubtypesHIV Research & Clinical Practice, 2002
- Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In VitroJournal of Virology, 2002
- Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 ProteinJournal of Virology, 2001
- Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites: Clinical Significance and Implications for Resistance to Protease InhibitorsAIDS Research and Human Retroviruses, 2000
- Comparison of Three Different Commercial Methods for Measuring Plasma Viraemia in Patients Infected with Non-B HIV-1 SubtypesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999